Work

Phase I trial of docetaxel/prednisone plus fractionated dose radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody 177lu-J591 in patients with metastatic, castration-resistant prostate cancer (mCRPC).

Year: 2014

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2014.32.15_suppl.5064

Authors: Scott T. Tagawa, Young E. Whang, Gurveen Kaur, Shankar Vallabhajosula, Paul J. Christos, Anastasia Nikolopoulou, Yuliya Jhanwar, Arif Sheikh, Adam Ireland, Carmen Garcias-Espana, Stanley J. Goldsmith, Himisha Beltran, Neil Harrison Bander, David M. Nanus

Institutions: Weill Cornell Medicine, University of North Carolina at Chapel Hill

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2467548170

Cites:

Cited by: 10

Related to: 10